Arvinas Inc Quick Ratio (ARVN) starting from the third quarter 2026 to third quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Arvinas Inc   (NASDAQ: ARVN)

Arvinas Inc 's Quick Ratio

ARVN's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Current Liabilities decreased faster than Arvinas Inc 's Cash & cash equivalent, this led to improvement in Arvinas Inc 's Quick Ratio to 7.98, above Arvinas Inc average Quick Ratio.

Within Major Pharmaceutical Preparations industry 149 other companies have achieved higher Quick Ratio than Arvinas Inc in third quarter 2026. While Quick Ratio total ranking has improved so far during the Q3 2026 to 558, from total ranking in the second quarter 2026 at 571.

Explain Quick Ratio?
How much Cash & cash equivalents ARVN´s has?
What are ARVN´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ARVN Quick Ratio (Sep 30 2026)
Q3		 (Jun 30 2026)
Q2		 (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3
Y / Y Current Liabilities Change -51.69 % 22.95 % -45.84 % -35.9 % -47.48 %
Y / Y Cash & cash equivalent Change -29.1 % -34.06 % -35.57 % -34.06 % -29.78 %
Quick Ratio MRQ 7.98 6.88 5.31 4.65 5.44
ARVN's Total Ranking # 558 # 571 # 460 # 481 #
Seq. Current Liabilities Change -15.15 % -28.82 % -21.32 % 1.66 % 115.95 %
Seq. Cash & cash equivalent Change -1.67 % -7.64 % -10.29 % -12.98 % -8.55 %



Quick Ratio third quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 150
Healthcare Sector # 234
Overall Market # 558


Quick Ratio Statistics
High Average Low
26.5 7.23 3.15
(Dec 31 2020)   (Sep 30 2023)




Financial Statements
Arvinas Inc 's Current Liabilities $ 70 Millions Visit ARVN's Balance sheet
Arvinas Inc 's Cash & cash equivalent $ 558 Millions Visit ARVN's Balance sheet
Source of ARVN's Sales Visit ARVN's Sales by Geography


Cumulative Arvinas Inc 's Quick Ratio

ARVN's Quick Ratio for the trailling 12 Months

ARVN Quick Ratio

 (Sep 30 2026)
12 Months		 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth -36.61 % -37.65 % -55.46 % -47.58 % -41.5 %
Y / Y Cash & cash equivalent TTM Growth -33.38 % -33.21 % -32.11 % -27.87 % -23.81 %
Quick Ratio TTM 5.84 5.41 6.21 5.74 5.55
Total Ranking TTM # 3621 # 2700 # 2421 # 2924 #
Seq. Current Liabilities TTM Growth -15.27 % 3.24 % -17.11 % -12.58 % -16.65 %
Seq. Cash & cash equivalent TTM Growth -8.63 % -9.95 % -10.32 % -9.72 % -8.4 %

Quick ratio ranking by company, industry and sector >> Back to ARVN Financial Strength Comparisons >> Go to Compare ARVN Quick Ratio to its Competitors

On the trailing twelve months basis Current Liabilities decreased faster than Arvinas Inc 's average Cash & cash equivalent, this led to increase in in Arvinas Inc 's Quick Ratio to 5.84, Quick Ratio remained below ARVN average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 422 other companies have achieved higher Quick Ratio than Arvinas Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 2700 to 3621.

Explain Quick Ratio?
How much Cash & cash equivalents ARVN´s has?
What are ARVN´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 423
Healthcare Sector # 860
Within the Market # 3621


trailing twelve months Quick Ratio Statistics
High Average Low
12.82 6.14 0.53
(Jun 30 2021)   (Dec 31 2018)




Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2026 MRQ Cash & cash equivalentSep 30 2026 MRQ Current Liabilities
Kailera Therapeutics Inc   21.40 $ 901.454  Millions$ 42.116  Millions
Cryoport inc   20.47 $ 653.343  Millions$ 31.911  Millions
Roivant Sciences Ltd   20.30 $ 5,683.045  Millions$ 279.911  Millions
Disc Medicine Inc   19.87 $ 682.816  Millions$ 34.360  Millions
Telomir Pharmaceuticals Inc   19.07 $ 4.516  Millions$ 0.237  Millions
Onkure Therapeutics Inc   18.58 $ 163.305  Millions$ 8.789  Millions
Siga Technologies Inc  17.27 $ 116.380  Millions$ 6.738  Millions
Keros Therapeutics Inc   16.36 $ 259.464  Millions$ 15.858  Millions
Design Therapeutics Inc   16.36 $ 208.608  Millions$ 12.753  Millions
Palvella Therapeutics Inc   15.85 $ 236.680  Millions$ 14.928  Millions
Avalo Therapeutics Inc   15.63 $ 392.966  Millions$ 25.135  Millions
Bioage Labs Inc   14.91 $ 283.637  Millions$ 19.027  Millions
Damora Therapeutics Inc   14.72 $ 528.478  Millions$ 35.892  Millions
Protagonist Therapeutics inc   14.42 $ 800.064  Millions$ 55.464  Millions
Praxis Precision Medicines Inc   14.20 $ 745.323  Millions$ 52.498  Millions
Tenax Therapeutics Inc   13.61 $ 113.700  Millions$ 8.355  Millions
Corvus Pharmaceuticals Inc   13.25 $ 204.252  Millions$ 15.418  Millions
Stablecoin Development Corporation  13.01 $ 7.153  Millions$ 0.550  Millions
Uniqure N v   12.78 $ 768.430  Millions$ 60.142  Millions
Rhythm Pharmaceuticals Inc   12.62 $ 320.944  Millions$ 25.438  Millions
Dyne Therapeutics Inc   12.53 $ 1,134.386  Millions$ 90.545  Millions
Sensei Biotherapeutics Inc   12.44 $ 174.795  Millions$ 14.049  Millions
Spyre Therapeutics Inc   12.24 $ 82.727  Millions$ 6.760  Millions
Edgewise Therapeutics inc   12.10 $ 1,743.893  Millions$ 144.106  Millions
Korro Bio Inc   11.06 $ 165.015  Millions$ 14.923  Millions
Xenon Pharmaceuticals Inc   10.99 $ 950.798  Millions$ 86.487  Millions
Newamsterdam Pharma Company N v   10.99 $ 628.242  Millions$ 57.154  Millions
Vtv Therapeutics Inc   10.99 $ 77.164  Millions$ 7.024  Millions
Abcellera Biologics Inc   10.85 $ 764.424  Millions$ 70.473  Millions
Cogent Biosciences Inc   10.82 $ 791.134  Millions$ 73.118  Millions

Date modified: 2026-11-04T15:06:30+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.